Quarterly Activities/Appendix 4C Cash Flow Report
Released
Released
Announcement PDF
ASX Announcement
Quarterly Cash Flow Statement & Operational Highlights
Highlights:
•
Regulatory approval received from Indonesia’s Drug and Food Authority for
Registrational Phase 3 Clinical Trial of RECCE® 327 Topical Gel (R327G) for
Diabetic Foot Infections
•
Ethics approval received to commence dosing in Indonesian Registrational Phase
3 Clinical Trial of R327G in Diabetic Foot Infections
•
Patient dosing complete for Phase II ABSSSI Clinical Trial with data readouts
expected Q1 CY25
•
A$6.75m Research & Development rebate received
•
Australia Patent Granted for RECCE® Anti-Infectives
SYDNEY Australia, 31 January 2025: Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (Recce
or the Company), the Company developing a New Class of Synthetic Anti-infectives, today
released its December 2024 quarter results and operational highlights.
Financial Update
The Company ended the quarter with a cash balance of A$1.94 million. Net cash outflows
from operating activities were (A$2.67 million), with Research and Development (A$2.79 million)
being the largest item of expenditure supporting ongoing human clinical trials, and the
advancement of late-stage pre-clinical studies. Payments to related parties (Executive &
Director fees) were (A$0.71 million).
Cash balance does not reflect Q3, 2024 announced U.S. Department of Defence Army burn wound
grant of US$2.0 million (A$3.21 million) or anticipated additional R&D advance funds.
A$6.75 million R&D Rebate Received
The Company announced a cash refund of AUD A$6.75 million Research and Development (R&D)
Tax Incentive rebate from the Australian Taxation Office for the financial year ending 30 June 2024.
The A$6.75 million reflects R&D activities undertaken locally and overseas, provided to the
Company in cash, without caveat. This receipt was used to repay advances from Endpoints Capital
reflecting R&D rebate credits for FY24. The advances Endpoints Capital provides as part of their
services, enable the Company to leverage its R&D benefits of the past, present and future R&D
applicable expenditure. Data shows drawing and re-deploying R&D applicable expenditure through
such a facility over the year, not only offsets applicable interest but also provides a net-positive
surplus to the Company having increased its total claimable R&D rebate over the period.
Operational Highlights
Regulatory approval received from Indonesia’s Drug and Food Authority for
Registrational Phase 3 Clinical Trial of R327G in Diabetic Foot Infections
The Company received approval from the Indonesian Drug and Food Regulatory Authority, Badan
POM, to initiate its Registrational Phase 3 clinical trial assessing RECCE® 327 as a topical gel
(R327G) for the treatment of diabetic foot infections (DFIs).
The trial will be conducted as a double-blinded, placebo-controlled study evaluating R327G for the
treatment of DFIs and aims to enrol up to 300 patients (200 to receive R327G and 100 to receive
placebo). The trial will run for approximately 12 months, with an expected read-out in late 2025 and
expected regulatory approval and commercial launch in H1 CY26.
Ethics approval received to commence dosing in Indonesian Registrational Phase 3
Clinical Trial of R327G in Diabetic Foot Infections
The Company received Human Research Ethics Committee approval to commence a
Registrational Phase 3 clinical trial of R327G for the treatment of DFIs. Ethics approval signifies
that Recce has met the safety and efficacy testing requirements to proceed with this large-scale,
late-stage clinical trial.
The approval process for the Indonesian clinical trial is now complete. Successfully completing this
trial would enable Recce to replicate regulatory approval for R327G across the broader ASEAN
region, including Malaysia, the Philippines, Singapore, and Thailand, as a treatment for DFIs,
addressing a critical unmet need for new therapeutics in countries facing increasing rates of
antimicrobial resistance and infectious diseases.
Patient dosing complete for Phase II ABSSSI Clinical Trial
The Company announced that an independent non-Data Safety Monitoring Board (non-DSMB) has
completed its review of safety and efficacy data from the Company’s ongoing Phase II clinical trial
of its lead compound, R327G, in patients with Acute Bacterial Skin and Skin Structure Infections
(ABSSSI) including DFIs.
Most patients treated with R327G demonstrated highly encouraging efficacy results, with all
patients completing treatment being positive on the primary endpoint and achieving either complete
cure or improvement, with many showing complete cure results as early as 7 days. These
outcomes were measured using the Lipsky Clinical Resolution of Infection Scale (Lipsky Scale), a
widely recognised tool for assessing the resolution of infections, particularly in diabetic foot
infections. Recognised by the FDA, the Lipsky Scale is an approved and reliable method for
evaluating the treatment of wound infections. The non-DSMB's positive findings further underscore
the strong safety profile of Recce’s innovative anti-infective therapy.
Post-quarter the Company announced that patient dosing is now complete with the successful
dosing of all 30 patients. The full set of clinical data will be reviewed by the Data Safety Monitoring
Board with full Phase II results expected to be announced in Q1 2025.
Australia Patent Granted for RECCE® Anti-Infectives
The Company announced the Australian Patent Office has formally granted Patent Family 3 for
Recce’s Anti-infectives through to 2037. This is the final step of Recce’s wholly owned patents
Granted for Family 3 and the final patent to be granted in Australia, with the Company now patent
protected in all major pharmaceutical markets globally.
Ord Minnett Biotech & MedTech Conference Presentation
Recce Pharmaceuticals CEO James Graham, presented at the Ord Minnett Biotech & MedTech
Conference, a copy of the presentation is available here.
Looking Ahead
Following recent Phase III clinical trial approvals, the Company is focused on achieving key
milestones, including the release of the Phase II ABSSSI clinical data report and the commencement
of the Phase III DFI clinical trial in Indonesia. Recce is well-positioned to deliver on its operational
and clinical goals in the coming quarter.
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
Recce Pharmaceuticals Ltd
ABN
Quarter ended (“current quarter”)
73 124 849 065
December 2024
Consolidated statement of cash flows
Current quarter
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
Year to date (6
months)
-
-
(2,794,339)
(10,385,848)
-
-
(403,183)
(1,113,458)
-
-
(e) staff costs
(670,189)
(1,248,196)
(f)
(243,224)
(1,137,435)
-
-
(a) research and development
(b) product manufacturing and operating
costs
(c) advertising and marketing
(d) leased assets
administration and corporate costs
1.3
Dividends received (see note 3)
1.4
Interest received
32,705
69,359
1.5
Interest and other costs of finance paid
(12,902)
(54,670)
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
6,825,961
6,839,871
1.8
Other
33,099
106,518
1.9
Net cash from / (used in) operating
activities
2,767,928
(6,923,860)
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(a) entities
-
-
(b) businesses
-
-
(11,805)
(17,947)
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
(c) property, plant and equipment
other non-current assets
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
2.2
Current quarter
Year to date (6
months)
Proceeds from disposal of:
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
other non-current assets
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (provide details if material)
(43,199)
(389,973)
2.6
Net cash from / (used in) investing
activities
(55,004)
(407,920)
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
-
12,530,005
3.2
Proceeds from issue of convertible debt
securities
-
-
3.3
Proceeds from exercise of options
-
-
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
-
(559,945)
3.5
Proceeds from borrowings
-
-
3.6
Repayment of borrowings
(7,095,658)
(7,095,658)
3.7
Transaction costs related to loans and
borrowings
-
-
3.8
Dividends paid
-
-
3.9
Other (provide details if material)
-
(14,000)
3.10
Net cash from / (used in) financing
activities
(7,095,658)
4,860,402
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
6,326,540
4,415,184
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
2,767,928
(6,923,860)
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
(55,004)
(407,920)
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
(7,095,658)
4,860,402
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
4.5
Effect of movement in exchange rates on
cash held
4.6
5.
Current quarter
Year to date (6
months)
-
-
Cash and cash equivalents at end of
period
1,943,806
1,943,806
Reconciliation of cash and cash
equivalents
Current quarter
Previous quarter
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
1,943,806
1,943,806
5.2
Call deposits
-
-
5.3
Bank overdrafts
-
-
5.4
Other – Trust Account
-
-
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
1,943,806
1,943,806
6.
Payments to related parties of the entity and their
associates
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
717,208
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
Nil
Current quarter
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
Amount drawn at
quarter end
7.1
Loan facilities
Nil
Nil
7.2
Credit standby arrangements
Nil
Nil
7.3
Other (please specify)
Nil
Nil
7.4
Total financing facilities
Nil
Nil
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
8.
Estimated cash available for future operating activities
8.1
Net cash from / (used in) operating activities (item 1.9)
2,767,928
8.2
Cash and cash equivalents at quarter end (item 4.6)
1,943,806
8.3
Unused finance facilities available at quarter end (item 7.5)
8.4
Total available funding (item 8.2 + item 8.3)
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
Nil
1,943,806
0.70
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer: Cash balance does not reflect Q3, 2024 announced US Department of Defence Army
burn wound grant of US$2.0m (AU$3.21m) with first receipt expected in the present quarter.
Further R&D Advance funds are also anticipated in present quarter.
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer: Yes, as above.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer: Yes, as above.
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
31 January 2025
Authorised by: The Board
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 5
Share your feedback
Discover